<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122208</url>
  </required_header>
  <id_info>
    <org_study_id>istanbulMU intensive care</org_study_id>
    <nct_id>NCT05122208</nct_id>
  </id_info>
  <brief_title>Famotidine in Covid-19 Intensive Care Unit</brief_title>
  <official_title>Clinical Effects of Famotidine Use in Intensive Care Covid-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 disease, caused by SARS-CoV-2 virus, started in December 2019 and created a&#xD;
      pandemic with high mortality and morbidity. Since a fully proven treatment has not been&#xD;
      developed, the efficacy of currently available treatments is being investigated. Famotidine,&#xD;
      an H2Receptor blocker, is one of the drug treatments being investigated. In this study, we&#xD;
      aimed to investigate the effect of Famotidine treatment on the clinic and mortality of&#xD;
      Covid-19 patients treated in the intensive care unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The computer and written records of the patients followed in the Covid-19 Intensive Care&#xD;
      Units of a research hospital during the pandemic process will be examined. Patients over the&#xD;
      age of 18 who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR (Polymeraze Chaine&#xD;
      Reaction) will be included in the study. Patients with immunosuppression, end-stage renal&#xD;
      disease, liver disease, G6PD deficiency, ALT/AST &gt;5, long QT syndrome in ECG, diagnosed with&#xD;
      psoriasis, porphyria, pregnant, and allergic reactions to famotidine or similar drugs were&#xD;
      excluded from the study. Patients' age, gender, comorbidities, smoking and APACHE II score&#xD;
      will be recorded. Patients who were administered Famotidine 160 mg/day PO or nasogastric and&#xD;
      were not given this treatment since their admission to the intensive care unit will be&#xD;
      compared. The primary outcome will be the need for invasive mechanical ventilation, intensive&#xD;
      care mortality, and both. As a secondary outcome, serum markers indicating the severity of&#xD;
      the disease (Leukocytes, lymphocytes, neutrophils/leukocytes, platelets, ferritin, CRP,&#xD;
      D-Dimer, fibrinogen, procalcitonin, IL-6, troponin, creatinine, AST, ALT, P/F ratio and&#xD;
      lactate) will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Actual">August 15, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date</time_frame>
    <description>Mortality in intensive care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Entubation</measure>
    <time_frame>Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date</time_frame>
    <description>Development of respiratory distress requiring intubation in the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameterr</measure>
    <time_frame>Within 17 days from the patient's admission to the intensive care unit or if he dies within this period, to this date</time_frame>
    <description>Leukocytes, lymphocytes, neutrophils/leukocytes, platelets, ferritin, CRP, D-Dimer, fibrinogen, procalcitonin, IL-6, troponin, creatinine, AST, ALT, P/F ratio and lactate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>COVID-19 Pandemic</condition>
  <arm_group>
    <arm_group_label>Famotidine Group</arm_group_label>
    <description>Patients who were administered Famotidine 160 mg/day PO or nasogastric.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Patients who were not administered Famotidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine Tablets</intervention_name>
    <description>160 mg/day Famotidine</description>
    <arm_group_label>Famotidine Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients followed in the Covid-19 Intensive Care Units&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have SARS-CoV-2 mRNA detected by nasopharyngeal PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunosuppression&#xD;
&#xD;
          -  end-stage renal disease&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  G6PD deficiency&#xD;
&#xD;
          -  long QT syndrome in ECG&#xD;
&#xD;
          -  psoriasis&#xD;
&#xD;
          -  porphyria&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  allergic reactions to famotidine or similar drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mesure Gul Nihan Ozden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Medeniyet University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul Medeniyet University</name>
      <address>
        <city>İ̇stanbul</city>
        <zip>34730</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>mesure gul nihan ozden</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19 Intensive Care Unit</keyword>
  <keyword>Famotidine</keyword>
  <keyword>mortality</keyword>
  <keyword>entubation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

